Acadian Asset Management LLC boosted its position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 10.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 156,319 shares of the medical equipment provider's stock after buying an additional 15,329 shares during the period. Acadian Asset Management LLC owned 1.23% of iRadimed worth $8,197,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in shares of iRadimed in the first quarter valued at approximately $369,000. Goldman Sachs Group Inc. raised its stake in shares of iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock valued at $8,889,000 after acquiring an additional 1,821 shares in the last quarter. Jones Financial Companies Lllp raised its stake in shares of iRadimed by 8,568.5% in the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock valued at $591,000 after acquiring an additional 11,139 shares in the last quarter. Uniplan Investment Counsel Inc. raised its stake in iRadimed by 49.7% in the first quarter. Uniplan Investment Counsel Inc. now owns 48,727 shares of the medical equipment provider's stock valued at $2,557,000 after buying an additional 16,187 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after buying an additional 234 shares in the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.
iRadimed Stock Performance
Shares of IRMD stock traded up $0.34 during mid-day trading on Monday, hitting $71.61. 39,081 shares of the stock were exchanged, compared to its average volume of 38,859. The stock's fifty day simple moving average is $66.32 and its two-hundred day simple moving average is $58.64. The stock has a market capitalization of $910.88 million, a price-to-earnings ratio of 44.20 and a beta of 1.01. iRadimed Corporation has a 12-month low of $46.86 and a 12-month high of $74.43.
iRadimed Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Thursday, August 28th. Investors of record on Monday, August 18th were issued a dividend of $0.17 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed's dividend payout ratio (DPR) is currently 41.98%.
Insiders Place Their Bets
In other iRadimed news, Director Monty K. Allen sold 1,102 shares of iRadimed stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $69.10, for a total value of $76,148.20. Following the sale, the director owned 19,898 shares of the company's stock, valued at approximately $1,374,951.80. The trade was a 5.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 36.80% of the company's stock.
iRadimed Profile
(
Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Articles

Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.